Tumoral lymphangiogenesis is fostered by tumor-derived VEGF-C and other lymphangiogenic growth factors such as angiopoietin 2 and fibroblast growth factor 2, which functionally interact with VEGFR3’s downstream effectors. The gene discussed is FLT4; the disease is neoplasm.